Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Thoracic 1Other hematologic neoplasm 1Dermatologic 1CNS 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Paclitaxel 2tislelizumab 1stenoparib 1sargramostim 1pembrolizumab 1margetuximab 1bintrafusp alfa protein, human 1Temozolomide 1Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1Paracentesis 1Palliative Care 1N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide 1Monatide (IMS 3015) 1Magnetic Resonance Spectroscopy 1Granulocyte-Macrophage Colony-Stimulating Factor 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × bintrafusp alfa protein, human × Other hematologic neoplasm × Clear all
NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 1/2 Terminated
8 enrolled 13 charts
BreastCNSDermatologicOther hematologic neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡